Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.55 |
| ▸ | HTR1A | P08908 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | MPI | P34949 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | CASR | P41180 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3422321 | 0.99 | ADRA2A (0.54) | ADRA2AADRA2BADRA2CADRA1AHTR1A | |
| SCHEMBL900644 | 0.89 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CADRA1AHTR1A | |
| SCHEMBL7886328 | 0.89 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CADRA1AHTR1A | |
| Hydrochloric Acid SCHEMBL900773 | 0.88 | ADRA2A (0.52) | ADRA2AADRA2BADRA2CADRA1AHTR1A | |
| SCHEMBL2899691 | 0.88 | MAPT (0.55) | ADRA2AADRA2BADRA2CADRA1AHTR1A | |
| Bromide SCHEMBL7147879 | 0.86 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CADRA1AHTR1A | |
| SCHEMBL2902371 | 0.86 | KDM4E (0.51) | ADRA2AADRA2BADRA2CADRA1AHTR1A | |
| Hydrochloric Acid SCHEMBL11357932 | 0.84 | KDM4E (0.54) | ADRA2AADRA2BADRA2CADRA1AHTR1A | |
| SCHEMBL7149054 | 0.83 | ADRA2A (0.56) | ADRA2AADRA2BADRA2CADRA1AHTR1A | |
| SCHEMBL11353783 | 0.81 | ENPP2 (0.52) | ADRA2AADRA2BADRA2CADRA1AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791839-B1 | PREPARATION OF 9-HYDROXY-3-(2-HYDROXYETHYL)-2-METHYL-4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE AND CRYSTALLS THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-10 | — | — | EP | claimed |
| WO-2012042368-A1 | PROCESS FOR PREPARATION OF PALIPERIDONE | AUROBINDO PHARMA LIMITED (IN) | 2012-04-05 | — | — | WO | claimed |
| WO-2011073997-A2 | PROCESS FOR PREPARING PALIPERIDONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2011-06-23 | — | — | WO | claimed |
| WO-2010082111-A1 | PREPARATION OF 3-(2-HYDROXY ETHYL)-9-HYDROXY-2-METHYL-4H-PYRIDO-[1,2-A]-PYRIMIDIN-4-ONE OR ITS ACID ADDITION SALT | CADILA PHARMACEUTICALS LTD. (IN) | 2010-07-22 | — | — | WO | claimed |
| US-7723518-B2 | Preparation of 9-hydroxy-3-(2-hydroxyethyl)-2-methyl-4H-pyrido[1,2-A]pyrimidin-4-one | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-05-25 | — | — | US | claimed |
| EP-2046790-A2 | PROCESS FOR THE SYNTHESIS OF CMHTP AND INTERMEDIATES THEREOF | Teva Pharmaceutical Industries Ltd. (IL) | 2009-04-15 | — | — | EP | claimed |
| WO-2008140646-A2 | PROCESS FOR THE SYNTHESIS OF CMHTP AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-11-20 | — | — | WO | claimed |
| US-20080214809-A1 | Process for the synthesis of CMHTP and intermediates thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-09-04 | — | — | US | claimed |
| US-20070260061-A1 | Preparation Of 9-Hydroxy -(2-Hydroxyethyl)-2-Methyl-4H-Pyrido[1,2-A]Pryimidin-4-One | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-08 | — | — | US | claimed |
| CN-101014601-A | Preparation of 9-hydroxy-3- (2-hydroxyethyl) -2-methyl-4h-pyrid0[1, 2-a] pyrimidin-4-one and crystalls thereof | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-08 | — | — | CN | claimed |
| EP-1791839-A1 | PREPARATION OF 9-HYDROXY-3- (2-HYDROXYETHYL) -2-METHYL-4H-PYRID0[1, 2-a]PYRIMIDIN-4-ONE AND CRYSTALS THEREOF | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-06 | — | — | EP | claimed |
| WO-2006027370-A1 | PREPARATION OF 9-HYDROXY-3- (2-HYDROXYETHYL) -2-METHYL-4H-PYRID0[1, 2-a] PYRIMIDIN-4-ONE AND CRYSTALS THEREOF | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-16 | — | — | WO | claimed |
| CN-117700411-B | Synthesis method of paliperidone key intermediate | 山东康诺生物工程有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-117700411-B | Synthesis method of paliperidone key intermediate | 山东康诺生物工程有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-117700411-A | Synthesis method of paliperidone key intermediate | 山东康诺生物工程有限公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-2303877-B1 | PROCESS TO PREPARE PALIPERIDONE AND INTERMEDIATES THEREOF | INKE SA (ES) | 2017-02-15 | — | — | EP | disclosed |
| EP-1791839-A1 | PREPARATION OF 9-HYDROXY-3- (2-HYDROXYETHYL) -2-METHYL-4H-PYRID0[1, 2-a]PYRIMIDIN-4-ONE AND CRYSTALS THEREOF | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006027370-A8 | PREPARATION OF 9-HYDROXY-3- (2-HYDROXYETHYL) -2-METHYL-4H-PYRID0[1, 2-a] PYRIMIDIN-4-ONE AND CRYSTALS THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006027370-A1 | PREPARATION OF 9-HYDROXY-3- (2-HYDROXYETHYL) -2-METHYL-4H-PYRID0[1, 2-a] PYRIMIDIN-4-ONE AND CRYSTALS THEREOF | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006027370-A1 | PREPARATION OF 9-HYDROXY-3- (2-HYDROXYETHYL) -2-METHYL-4H-PYRID0[1, 2-a] PYRIMIDIN-4-ONE AND CRYSTALS THEREOF | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214809-A1 | Process for the synthesis of CMHTP and intermediates thereof | HAMP, TPMT, MPHOSPH6 | ADRA2A 1411/4885ADRA2B 1034/4885ADRA2C 1304/4885 |
| US-20070260061-A1 | Preparation Of 9-Hydroxy -(2-Hydroxyethyl)-2-Methyl-4H-Pyrido[1,2-A]Pryimidin-4-One | HTR1B, PTMS, CHRNA4 | ADRA2A 161/4885ADRA2B 54/4885ADRA2C 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.